The stock of CoLucid Pharmaceuticals Inc (NASDAQ:CLCD) is a huge mover today! About 183,813 shares traded hands. CoLucid Pharmaceuticals Inc (NASDAQ:CLCD) has risen 421.29% since March 7, 2016 and is uptrending. It has outperformed by 413.70% the S&P500.
The move comes after 9 months positive chart setup for the $689.81 million company. It was reported on Oct, 10 by Barchart.com. We have $57.20 PT which if reached, will make NASDAQ:CLCD worth $372.50M more.
Analysts await CoLucid Pharmaceuticals Inc (NASDAQ:CLCD) to report earnings on November, 8. They expect $-0.97 earnings per share, down 64.41% or $0.38 from last year’s $-0.59 per share. After $-1.06 actual earnings per share reported by CoLucid Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts -8.49% EPS growth.
CoLucid Pharmaceuticals Inc (NASDAQ:CLCD) Ratings Coverage
Out of 2 analysts covering CoLucid Pharmaceuticals (NASDAQ:CLCD), 1 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 50% are positive. CoLucid Pharmaceuticals has been the topic of 3 analyst reports since August 14, 2015 according to StockzIntelligence Inc. The rating was maintained by Stifel Nicolaus on Monday, September 19 with “Buy”. The firm has “Hold” rating given on Thursday, September 3 by Zacks. On Friday, August 14 the stock rating was maintained by William Blair with “Buy”.
According to Zacks Investment Research, “CoLucid Pharmaceuticals, Inc. is a biopharmaceutical company which develops molecule for the treatment of migraine headaches. The company’s product candidate consists of oral Lasmiditan for the treatment of migraine headache and intravenous lasmiditan for treatment of headache pain, which are in different clinical trial. CoLucid Pharmaceuticals, Inc. is headquartered in Burlington, Massachusetts.”
More news for CoLucid Pharmaceuticals Inc (NASDAQ:CLCD) were recently published by: Fool.com, which released: “Why CoLucid Pharmaceuticals Inc. Soared As Much As 18% on Thursday” on September 15, 2016. Globenewswire.com‘s article titled: “CoLucid Pharmaceuticals Announces Pricing of Public Offering of Common Stock” and published on September 09, 2016 is yet another important article.
CLCD Company Profile
CoLucid Pharmaceuticals, Inc., incorporated on August 31, 2005, is a Phase III clinical-stage biopharmaceutical company. The Firm is engaged in developing a small molecule for the acute treatment of migraine headaches. The Company’s product candidates address the needs of migraine patients, including those with cardiovascular risk factors or stable cardiovascular disease and those dissatisfied with existing therapies. Lasmiditan, the Company’s lead product candidate, is an oral tablet for the acute treatment of migraine in adults. Lasmiditan selectively targets 5-HT1F receptors expressed in the trigeminal pathway in the central nervous system (CNS). Lasmiditan is designed to penetrate the CNS and block the pathway that contributes to headache pain.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.